18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
Completed · NCT04647214
Conditions: Open-angle Glaucoma, Ocular Hypertension
At a glance
- Research payments reported, 2025
- $209,652
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 220
About the trial
- Sponsor
- Allergan
- Dates
- Started 2021-03-03; completion 2024-07-12
- Results posted
- Not yet
Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
From ClinicalTrials.gov, last updated 2025-08-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $209,652 in research payments for this study in 2025 (4 payments).
Products named: Durysta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mujtaba A. Qazi, M.D. Ophthalmology · Chesterfield, MO
- Katy Liu, M.D., PH.D. Ophthalmology · Durham, NC
- Pankajkumar G. Shah, MD Ophthalmology · Mission, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dct - Shah Research LLC $208,409
- Duke University $1,063
- Midwest Vision Research F $180
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.